Leucine and ACE inhibitors as therapies for sarcopenia (LACE trial): study protocol for a randomised controlled trial
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Sarcopenia (the age-related loss of muscle mass and function) is a major contributor to loss of mobility, falls, loss of independence, morbidity and mortality in older people. Although resistance training is effective in preventing and reversing sarcopenia, many older people are sedentary and either cannot or do not want to exercise. This trial examines the efficacy of supplementation with the amino acid leucine and/or angiotensin converting enzyme inhibition to potentially improve muscle mass and function in people with sarcopenia. Promising preliminary data exist from small studies for both interventions, but neither has yet been tested in adequately powered randomised trials in patients with sarcopenia. METHODS: Leucine and ACE inhibitors in sarcopenia (LACE) is a multicentre, masked, placebo-controlled, 2 × 2 factorial randomised trial evaluating the efficacy of leucine and perindopril (angiotensin converting enzyme inhibitor (ACEi)) in patients with sarcopenia. The trial will recruit 440 patients from primary and secondary care services across the UK. Male and female patients aged 70 years and over with sarcopenia as defined by the European Working Group on Sarcopenia (based on low total skeletal muscle mass on bioimpedance analysis and either low gait speed or low handgrip strength) will be eligible for participation. Participants will be excluded if they have a contraindication to, or are already taking, an ACEi, angiotensin receptor blocker or leucine. The primary clinical outcome for the trial is the between-group difference in the Short Physical Performance Battery score at all points between baseline and 12 months. Secondary outcomes include appendicular muscle mass measured using dual-energy X-ray absorptiometry, muscle strength, activities of daily living, quality of life, activity using pedometer step counts and falls. Participants, clinical teams, outcomes assessors and trial analysts are masked to treatment allocation. A panel of biomarkers including microRNAs, neurohormones, genetic polymorphisms and markers of inflammation relevant to muscle pathophysiology will be measured to explore predictors of response and further elucidate mechanisms underlying sarcopenia. Participants will receive a total of 12 months of either perindopril or placebo and either leucine or placebo. DISCUSSION: The results will provide the first robust test of the overall clinical and cost-effectiveness of these novel therapies for older patients with sarcopenia. TRIAL REGISTRATION: ISRCTN, ISRCTN90094835 . Registered on 18 February 2015.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interventions for enhancing medication adherence
Nieuwlaat, R., Wilczynski, N., Navarro, T., Hobson, N., Jeffery, R., Keepanasseril, A., Agoritsas, T., Mistry, N., Iorio, A., Jack, S., et al. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000011.pub4 · Cited by 2,945 · cited 1×
“Interventions incorporating these components have been shown in a Cochrane review to enhance adherence [31].”
Studenski, S. A., Peters, K. W., Alley, D. E., Cawthon, P. M., McLean, R. R., Harris, T. B., Ferrucci, L., Guralnik, J. M., Fragala, M. S., Kenny, A. M., et al. (2014) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glu010 · Cited by 2,545 · cited 1×
“Thresholds for muscle mass are derived from the UK Biobank cohort [29] and are stratified by body mass index for each sex; such an approach ensures that participants with sarcopenic obesity are represented in the trial and is consistent with the more recent Foundation for the National Institutes of Health (FNIH) conse…”
Cruz-Jentoft, A. J., Landi, F., Schneider, S. M., Zuniga, C., Arai, H., Boirie, Y., Chen, L.-K., Fielding, R. A., Martin, F. C., Michel, J.-P., et al. (2014) · Age and Ageing · doi:10.1093/ageing/afu115 · Cited by 1,963
Estimation of skeletal muscle mass by bioelectrical impedance analysis
Janssen, I., Heymsfield, S. B., Baumgartner, R. N., & Ross, R. (2000) · Journal of Applied Physiology · doi:10.1152/jappl.2000.89.2.465 · Cited by 1,482 · cited 1×
“Initial screening criteria for muscle mass in the trial used the Janssen equation to calculate muscle mass [48], and used conservative thresholds for total skeletal muscle mass: 13 kg for women and 20.”
Anabolic signaling deficits underlie amino acid resistance of wasting, aging muscle
Cuthbertson, D., Smith, K., Babraj, J., Leese, G., Waddell, T., Atherton, P., Wackerhage, H., Taylor, P. M., & Rennie, M. J. (2005) · The FASEB Journal · doi:10.1096/fj.04-2640fje · Cited by 1,211 · cited 1×
“there is anabolic resistance to protein supplementation) [5].”
Self-citationTieland, M., Dirks, M. L., van der Zwaluw, N., Verdijk, L. B., van de Rest, O., de Groot, L. C. P. G. M., & van Loon, L. J. C. (2012) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2012.05.020 · Cited by 556 · cited 1×
“In contrast, in older participants undergoing resistance training, protein supplementation enhanced muscle mass, but not muscle strength or performance compared to placebo [21], suggesting that it is the non-exercising majority of older, frail people who are most likely to benefit from nutritional efforts to enhance m…”
Sergi, G., De Rui, M., Veronese, N., Bolzetta, F., Berton, L., Carraro, S., Bano, G., Coin, A., Manzato, E., & Perissinotto, E. (2015) · Clinical Nutrition · doi:10.1016/j.clnu.2014.07.010 · Cited by 467 · cited 1×
“[28]; this equation was developed in a white, older European population using the BIA 101 machine.”
Tieland, M., van de Rest, O., Dirks, M. L., van der Zwaluw, N., Mensink, M., van Loon, L. J. C., & de Groot, L. C. P. G. M. (2012) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2012.07.005 · Cited by 446 · cited 1×
“0-point improvement at 24 weeks) [20] but no improvement in skeletal muscle mass over this short follow-up period.”
Rieu, I., Balage, M., Sornet, C., Giraudet, C., Pujos, E., Grizard, J., Mosoni, L., & Dardevet, D. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2006.110742 · Cited by 410
Onder, G., Penninx, B. W., Balkrishnan, R., Fried, L. P., Chaves, P. H., Williamson, J., Carter, C., Bari, M. D., Guralnik, J. M., & Pahor, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08024-8 · Cited by 339 · cited 1×
“studies report better muscle strength and larger lower extremity mass in older people taking an ACEi [23, 24].”
Cited by
Sarcopenia: assessment of disease burden and strategies to improve outcomes
Liguori, I., Russo, G., Aran, L., Bulli, G., Curcio, F., Della-Morte, D., Gargiulo, G., Testa, G., Cacciatore, F., Bonaduce, D., et al. (2018) · Clinical Interventions in Aging · doi:10.2147/cia.s149232 · Cited by 300
the Sarcopenia Guidelines Development group of the Belgian Society of Gerontology and Geriatrics (BSGG), De Spiegeleer, A., Beckwée, D., Bautmans, I., & Petrovic, M. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0566-y · Cited by 160
Dietary Protein and Muscle in Aging People: The Potential Role of the Gut Microbiome
Ni Lochlainn, M., Bowyer, R. C. E., & Steves, C. J. (2018) · doi:10.20944/preprints201806.0152.v1 · Cited by 138
Dinan, L., Dioh, W., Veillet, S., & Lafont, R. (2021) · Biomedicines · doi:10.3390/biomedicines9050492 · Cited by 99
Bauer, J. M., Cruz-Jentoft, A. J., Fielding, R. A., Kanis, J. A., Reginster, J.-Y., Bruyère, O., Cesari, M., Chapurlat, R., Al-Daghri, N., Dennison, E., et al. (2019) · Calcified Tissue International · doi:10.1007/s00223-019-00561-w · Cited by 83
Metadata
- Authors
- Band, M. M., Sumukadas, D., Struthers, A. D., Avenell, A., Donnan, P. T., Kemp, P. R., Smith, K. T., Hume, C. L., Hapca, A., & Witham, M. D.
- Venue
- Trials
- Published
- 2018-01-04
- Volume
- 19
- Issue
- 1
- Pages
- 6-6
- ISSN
- 1745-6215 (ISSN-L)
- OpenAlex
- W2782016135
- Cited by
- 53
- References
- 17
- FWCI
- 4.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Leucine and ACE inhibitors as therapies for sarcopenia (LACE trial): study protocol for a randomised controlled trial. https://app.cochat.ai/papers/10.1186/s13063-017-2390-9
- The paper
- Band, M. M., Sumukadas, D., Struthers, A. D., Avenell, A., Donnan, P. T., Kemp, P. R., Smith, K. T., Hume, C. L., Hapca, A., & Witham, M. D. (2018). Leucine and ACE inhibitors as therapies for sarcopenia (LACE trial): study protocol for a randomised controlled trial. Trials. https://doi.org/10.1186/s13063-017-2390-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.